Hikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Recommendation of “Buy” from Analysts

Hikma Pharmaceuticals PLC (LON:HIK) has been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock in the last year is GBX 2,060.

HIK has been the topic of a number of recent research reports. Jefferies Financial Group increased their price objective on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Berenberg Bank boosted their target price on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Finally, Citigroup lifted their price objective on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research report on Wednesday.

Insiders Place Their Bets

In other Hikma Pharmaceuticals news, insider Tobias Hestler acquired 7,500 shares of Hikma Pharmaceuticals stock in a transaction on Monday, August 10th. The shares were purchased at an average cost of GBX 1,648 per share, with a total value of £123,600. 22.04% of the stock is owned by corporate insiders.

Hikma Pharmaceuticals Trading Down 0.2%

HIK opened at GBX 1,640 on Monday. Hikma Pharmaceuticals has a 1-year low of GBX 1,187 and a 1-year high of GBX 1,865. The stock has a market capitalization of £3.43 billion, a PE ratio of 9.06, a PEG ratio of 2.38 and a beta of 0.66. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. The firm has a 50-day moving average price of GBX 1,554.45 and a two-hundred day moving average price of GBX 1,456.86.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.